Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.44 |
| ▸ | GCK | P35557 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103772 | 0.85 | CHRNB2 (0.52) | CHRNB2CHRNA4CYP11B2 | |
| SCHEMBL13097262 | 0.83 | CHRNB4 (0.46) | CHRNB2CHRNA4GCKCYP11B2PDE2A | |
| SCHEMBL3577214 | 0.74 | TSHR (0.55) | CHRNB2CHRNA4 | |
| SCHEMBL113189 | 0.74 | CYP11B1 (0.40) | CHRNB2CHRNA4CYP11B2 | |
| SCHEMBL19668758 | 0.74 | CHRNB2 (0.46) | CHRNB2CHRNA4 | |
| SCHEMBL15716501 | 0.73 | CHRNB2 (0.58) | CHRNB2CHRNA4 | |
| SCHEMBL15884439 | 0.73 | HRH3 (0.54) | — | |
| SCHEMBL15884393 | 0.73 | KDM4C (0.49) | CHRNB2CHRNA4 | |
| SCHEMBL30542315 | 0.73 | KDM4C (0.49) | CHRNB2CHRNA4 | |
| SCHEMBL28467612 | 0.72 | CHRNB2 (0.40) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | CHRNB2 3048/4885CHRNA4 1760/4885GCK 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.